Gain Therapeutics (GANX) Invested Capital (2020 - 2025)
Historic Invested Capital for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $6.0 million.
- Gain Therapeutics' Invested Capital fell 3315.02% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 3315.02%. This contributed to the annual value of $7.4 million for FY2024, which is 4132.68% down from last year.
- Per Gain Therapeutics' latest filing, its Invested Capital stood at $6.0 million for Q3 2025, which was down 3315.02% from $3.8 million recorded in Q2 2025.
- Gain Therapeutics' Invested Capital's 5-year high stood at $44.5 million during Q1 2021, with a 5-year trough of $3.8 million in Q2 2025.
- Moreover, its 5-year median value for Invested Capital was $12.7 million (2023), whereas its average is $18.9 million.
- Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 46102.06% in 2021, then plummeted by 6786.97% in 2025.
- Quarter analysis of 5 years shows Gain Therapeutics' Invested Capital stood at $34.9 million in 2021, then crashed by 45.63% to $19.0 million in 2022, then plummeted by 33.13% to $12.7 million in 2023, then plummeted by 41.33% to $7.4 million in 2024, then fell by 18.99% to $6.0 million in 2025.
- Its Invested Capital stands at $6.0 million for Q3 2025, versus $3.8 million for Q2 2025 and $5.9 million for Q1 2025.